Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Rami Klaff, Eberhard Varenhorst, Anders Berglund, Per Olov Hedlund, Folke Sjöberg & Gabriel Sandblom. (2016) Clinical presentation and predictors of survival related to extent of bone metastasis in 900 prostate cancer patients. Scandinavian Journal of Urology 50:5, pages 352-359.
Read now
Read now
Per Olov Hedlund, Robert Johansson, Jan Erik Damber, Inger Hagerman, Peter Henriksson, Peter Iversen, Peter Klarskov, Peter Mogensen, Finn Rasmussen & Eberhard Varenhorst. (2011) Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: Evaluation of cardiovascular events in a randomized trial. Scandinavian Journal of Urology and Nephrology 45:5, pages 346-353.
Read now
Read now
Per Olov Hedlund, Jan-Erik Damber, Inger Hagerman, Svein Haukaas, Peter Henriksson, Peter Iversen, Robert Johansson, Peter Klarskov, Finn Lundbeck, Finn Rasmussen, Eberhard Varenhorst, Jouko Viitanen, Per Olov Hedlund, Jan-Erik Damber, Inger Hagerman, Svein Haukaas, Peter Henriksson, Peter Iversen, Robert Johansson, Peter Klarskov, Finn Lundbeck, Finn Rasmussen, Eberhard Varenhorst & Jouko Viitanen. (2008) Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: Part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scandinavian Journal of Urology and Nephrology 42:3, pages 220-229.
Read now
Read now
Pavlos Msaouel, Evanthia Diamanti, Marinela Tzanela & Michael Koutsilieris. (2007) Luteinising hormone-releasing hormone antagonists in prostate cancer therapy. Expert Opinion on Emerging Drugs 12:2, pages 285-299.
Read now
Read now
Morten Jønler, Ole Steen Nielsen, Mogens Groenvold, Per Olov Hedlund, Lena Damber, Hans Hedelin & Mauritz Waldén. (2005) Quality of life in patients with skeletal metastases of prostate cancer and status prior to start of endocrine therapy: Results from the scandinavian prostate cancer group study 5. Scandinavian Journal of Urology and Nephrology 39:1, pages 42-48.
Read now
Read now
Arto Mikkola, Jussi Aro, Sakari Rannikko, Hanna Oksanen & Mirja Ruutu. (2005) Cardiovascular complications in patients with advanced prostatic cancer treated by means of orchiectomy or polyestradiol phosphate. Scandinavian Journal of Urology and Nephrology 39:4, pages 294-300.
Read now
Read now
Articles from other publishers (30)
Zhen Liang, Jun Zhu, Longlong Chen, Yawei Xu, Yongjiao Yang, Rui Hu, Wei Zhang, Yuxuan Song, Yi Lu, Ningjing Ou & Xiaoqiang Liu. (2019) Is androgen deprivation therapy for prostate cancer associated with cardiovascular disease? A meta‐analysis and systematic review. Andrology 8:3, pages 559-574.
Crossref
Crossref
Muhammed Rashid, Madhan Ramesh, K. Shamshavali, Amit Dang, Himanshu Patel & Krishna Undela. (2020) Efficacy and Safety of Non-Steroidal Anti-Androgens in Patients with Metastatic Prostate Cancer: Meta-Analysis of Randomized Controlled Trials. Reviews on Recent Clinical Trials 15:1, pages 34-47.
Crossref
Crossref
Mark J. Salji, Imran Ahmad, Sarah Slater, Fat‐Wui Poon, Abdulla Alhasso, Nadja V. Melquiot, Holly Bekarma, Jane Hendry & Hing Y. Leung. 2019. Blandy's Urology. Blandy's Urology
563
609
.
Rami Klaff, Anders Berglund, Eberhard Varenhorst, Per Olov Hedlund, Morten Jǿnler & Gabriel Sandblom. (2015) Clinical characteristics and quality‐of‐life in patients surviving a decade of prostate cancer with bone metastases. BJU International 117:6, pages 904-913.
Crossref
Crossref
Eberhard Varenhorst, Rami Klaff, Anders Berglund, Per Olov Hedlund & Gabriel Sandblom. (2016) Predictors of early androgen deprivation treatment failure in prostate cancer with bone metastases. Cancer Medicine 5:3, pages 407-414.
Crossref
Crossref
Karim Fizazi, Per-Anders Abrahamsson, Goran Ahlgren, Joaquim Bellmunt, Daniel Castellano, Stephane Culine, Ronald de Wit, Silke Gillessen, Juergen E. Gschwend, Freddie Hamdy, Nicholas James, Raymond McDermott, Kurt Miller, Thomas Wiegel, Manfred Wirth & Bertrand Tombal. (2015) Achievements and Perspectives in Prostate Cancer Phase 3 Trials from Genitourinary Research Groups in Europe: Introducing the Prostate Cancer Consortium in Europe. European Urology 67:5, pages 904-912.
Crossref
Crossref
Ruth E Langley, Fay H Cafferty, Abdulla A Alhasso, Stuart D Rosen, Subramanian Kanaga Sundaram, Suzanne C Freeman, Philip Pollock, Rachel C Jinks, Ian F Godsland, Roger Kockelbergh, Noel W Clarke, Howard G Kynaston, Mahesh KB Parmar & Paul D Abel. (2013) Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09). The Lancet Oncology 14:4, pages 306-316.
Crossref
Crossref
Teuvo L.J. Tammela. (2012) Endocrine prevention and treatment of prostate cancer. Molecular and Cellular Endocrinology 360:1-2, pages 59-67.
Crossref
Crossref
Mark SteinSusan GoodinSusan Doyle-LindrudJeffery Silberberg, MIchael KaneDorinda MetzgerSimantini EddyWeichung ShihRobert S. DiPaola. (2012) Transdermal estradiol in castrate and chemotherapy resistant prostate cancer. Medical Science Monitor 18:4, pages CR260-CR264.
Crossref
Crossref
D. Schilling, G. Gakis, U. Bökeler, A. Stenzl, M.A. Kuczyk & A.S. Merseburger. (2009) Sekundäre Hormonablation beim hormonunabhängigen ProstatakarzinomSecondary hormonal ablation in hormone-independent prostate cancer. Der Urologe 48:2, pages 183-190.
Crossref
Crossref
T. Lebret & A. Méjean. (2008) Prise en charge du cancer de prostate métastasé androgéno-indépendant. Progrès en Urologie 18, pages S343-S348.
Crossref
Crossref
. 2008. Treatment Methods for Early and Advanced Prostate Cancer. Treatment Methods for Early and Advanced Prostate Cancer
295
296
.
Arto K.K. Mikkola, Jussi L.V. Aro, A.S. Sakari Rannikko & Mirja L. Ruutu. (2007) A high pretreatment plasma oestradiol level is associated with a low risk of acute myocardial infarction in parenteral oestrogen therapy for locally advanced prostate cancer. BJU International 101:9, pages 1090-1095.
Crossref
Crossref
A. Heidenreich, D. Pfister, C.H. Ohlmann & U.H. Engelmann. (2008) Androgendeprivation in der Therapie des ProstatakarzinomsAndrogen deprivation for advanced prostate cancer. Der Urologe 47:3, pages 270-283.
Crossref
Crossref
G Norman, M E Dean, R E Langley, Z C Hodges, G Ritchie, M K B Parmar, M R Sydes, P Abel & A J Eastwood. (2008) Parenteral oestrogen in the treatment of prostate cancer: a systematic review. British Journal of Cancer 98:4, pages 697-707.
Crossref
Crossref
Sophie D. Fosså, Anne-Birgitte Jacobsen, Claes Ginman, Inga N. Jacobsen, Sissel Overn, Jon R. Iversen, Thomas Urnes, Alv A. Dahl, Marijke Veenstra & Berit Sandstad. (2007) Weekly Docetaxel and Prednisolone versus Prednisolone Alone in Androgen-Independent Prostate Cancer: A Randomized Phase II Study. European Urology 52:6, pages 1691-1699.
Crossref
Crossref
Åsa Tivesten, Dan Mellström, Hans Jutberger, Björn Fagerberg, Bodil Lernfelt, Eric Orwoll, Magnus K. Karlsson, Östen Ljunggren & Claes Ohlsson. (2007) Low Serum Testosterone and High Serum Estradiol Associate With Lower Extremity Peripheral Arterial Disease in Elderly Men. Journal of the American College of Cardiology 50:11, pages 1070-1076.
Crossref
Crossref
Arto Mikkola, Jussi Aro, Sakari Rannikko & Mirja Ruutu. (2007) Ten‐year survival and cardiovascular mortality in patients with advanced prostate cancer primarily treated by intramuscular polyestradiol phosphate or orchiectomy. The Prostate 67:4, pages 447-455.
Crossref
Crossref
Jennifer L. Lycette, Lisa B. Bland, Mark Garzotto & Tomasz M. Beer. (2006) Parenteral Estrogens for Prostate Cancer: Can a New Route of Administration Overcome Old Toxicities?. Clinical Genitourinary Cancer 5:3, pages 198-205.
Crossref
Crossref
Åsa Tivesten, Johannes Hulthe, Karin Wallenfeldt, John Wikstrand, Claes Ohlsson & Björn Fagerberg. (2006) Circulating Estradiol Is an Independent Predictor of Progression of Carotid Artery Intima-Media Thickness in Middle-Aged Men. The Journal of Clinical Endocrinology & Metabolism 91:11, pages 4433-4437.
Crossref
Crossref
Jeremy Ockrim, El-Nasir Lalani & Paul Abel. (2006) Therapy Insight: parenteral estrogen treatment for prostate cancer—a new dawn for an old therapy. Nature Clinical Practice Oncology 3:10, pages 552-563.
Crossref
Crossref
Timothy J. Daskivich & William K. Oh. (2006) Recent progress in hormonal therapy for advanced prostate cancer. Current Opinion in Urology 16:3, pages 173-178.
Crossref
Crossref
JEREMY L. OCKRIM, EL‐NASIR LALANI, MO ASLAM, NIGEL STANDFIELD & PAUL D. ABEL. (2006) Changes in vascular flow after transdermal oestradiol therapy for prostate cancer: a mechanism for cardiovascular toxicity and benefit?. BJU International 97:3, pages 498-504.
Crossref
Crossref
Jonathan Q. Purnell, Lisa B. Bland, Mark Garzotto, Dianne Lemmon, Emily M. Wersinger, Christopher W. Ryan, John D. Brunzell & Tomasz M. Beer. (2006) Effects of transdermal estrogen on levels of lipids, lipase activity, and inflammatory markers in men with prostate cancer. Journal of Lipid Research 47:2, pages 349-355.
Crossref
Crossref
JEREMY L. OCKRIM, EL-NASIR LALANI, AJAY K. KAKKAR & PAUL D. ABEL. (2005) TRANSDERMAL ESTRADIOL THERAPY FOR PROSTATE CANCER REDUCES THROMBOPHILIC ACTIVATION AND PROTECTS AGAINST THROMBOEMBOLISM. Journal of Urology 174:2, pages 527-533.
Crossref
Crossref
Lisa B. Bland, Mark Garzotto, Thomas G. DeLoughery, Christopher W. Ryan, Kathryn G. Schuff, Emily M. Wersinger, Dianne Lemmon & Tomasz M. Beer. (2005) Phase II study of transdermal estradiol in androgen‐independent prostate carcinoma. Cancer 103:4, pages 717-723.
Crossref
Crossref
Chris F Heyns. (2005) Triptorelin in the Treatment of Prostate Cancer. American Journal of Cancer 4:3, pages 169-183.
Crossref
Crossref
Teuvo Tammela. (2004) Endocrine treatment of prostate cancer. The Journal of Steroid Biochemistry and Molecular Biology 92:4, pages 287-295.
Crossref
Crossref
D Kirk. (2004) Timing and choice of androgen ablation. Prostate Cancer and Prostatic Diseases 7:3, pages 217-222.
Crossref
Crossref
Aldo V Bono. (2004) Overview of Current Treatment Strategies in Prostate Cancer. European Urology Supplements 3:1, pages 2-7.
Crossref
Crossref